Celsee Inc., a provider of single-cell isolation technology in Ann Arbor, is selling some of its Genesis Systems, which monitor circulating tumor cells in lung, breast, and bladder cancers as well as offer options for single-cell research, to Kindstar Laboratory System in China. Kindstar will also become a distributor of Celsee’s products.
“We are very excited to announce the partnership with Kindstar and the opportunity to bring Celsee technology to the clinical research market in China,” says John Stark, CEO of Celsee. “Our team has worked closely with IncellDx to develop workflows that combine our single-cell tools with their flow cytometry classification assays and BioINK assays for CTC enumeration to assess disease progression and response to therapy.”
For the cancer research, Kindstar scientists will use the BioINK kit, which was developed by IncellDx for CTC enumeration in therapeutic monitoring and is performed on Celsee’s Genesis System using the Celselect Technology.
“Kindstar Global is leading the way for oncology research and testing in China, and we are committed to implementing the most advanced tools for that work,” says Shiang Huang, founder and CEO of Kindstar. “We are truly impressed by the capabilities of Celsee’s single-cell isolation and enumeration technology and are eager to use it in our own laboratories as well as to make it available to scientists throughout China.”
Celsee’s technology enables high-throughput analysis of single cells.
Kindstar offers more than 3,000 medical tests in more than 3,000 hospitals. It also provides medical research, clinical trial services, and translational medicine study services to physicians, medical science, and technology institutions and pharmaceutical companies.